Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010067
Filing Date
2025-05-14
Accepted
2025-05-14 06:05:39
Documents
43
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 517655
2 EX-31.1 ex31-1.htm EX-31.1 14688
3 EX-31.2 ex31-2.htm EX-31.2 14679
4 EX-32.1 ex32-1.htm EX-32.1 5362
5 EX-32.2 ex32-2.htm EX-32.2 5353
  Complete submission text file 0001641172-25-010067.txt   2874785

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE nxen-20250331.xsd EX-101.SCH 22167
7 XBRL CALCULATION FILE nxen-20250331_cal.xml EX-101.CAL 26116
8 XBRL DEFINITION FILE nxen-20250331_def.xml EX-101.DEF 99747
9 XBRL LABEL FILE nxen-20250331_lab.xml EX-101.LAB 213411
10 XBRL PRESENTATION FILE nxen-20250331_pre.xml EX-101.PRE 162521
45 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 325903
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 25942491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)